SGIOF:OTC-Shionogi & Co. Ltd (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 49.6

Change

0.00 (0.00)%

Market Cap

USD 14.21B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKKGY Merck KGaA ADR

-0.30 (-0.82%)

USD 79.59B
MKGAF MERCK Kommanditgesellschaft au..

-2.50 (-1.37%)

USD 77.98B
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD 41.30B
HLNCF Haleon plc

-0.02 (-0.50%)

USD 37.62B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 18.32B
SGIOY Shionogi & Co Ltd ADR

-0.09 (-0.78%)

USD 13.81B
ESALF Eisai Co. Ltd

N/A

USD 12.59B
ESAIY Eisai Co. Ltd.

-0.12 (-1.10%)

USD 12.54B
IPSEY Ipsen SA ADR

N/A

USD 10.63B
IPSEF Ipsen S.A

N/A

USD 10.63B

ETFs Containing SGIOF

1638:TSE 5.54 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.34% 59% D- 64% D
Dividend Return 1.21% 40% F 31% F
Total Return 8.54% 60% D- 65% D
Trailing 12 Months  
Capital Gain 8.23% 72% C 69% C-
Dividend Return 2.43% 46% F 34% F
Total Return 10.66% 72% C 69% C-
Trailing 5 Years  
Capital Gain -16.17% 84% B 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.17% 83% B 53% F
Average Annual (5 Year Horizon)  
Capital Gain -3.43% 53% F 32% F
Dividend Return 20.26% 70% C- 63% D
Total Return 23.69% 81% B- 93% A
Risk Return Profile  
Volatility (Standard Deviation) 36.43% 80% B- 63% D
Risk Adjusted Return 55.62% 97% N/A 90% A-
Market Capitalization 14.21B 99% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector